Venetoclax, Lenalidomide and Rituximab in Patients With Relapsed/Refractory Mantle Cell Lymphoma

Nordic Lymphoma Group17 sites in 4 countries59 target enrollmentJuly 1, 2018

ConditionsRelapsed Non Hodgkin Lymphoma

InterventionsVenetoclax

DrugsVenetoclax

Overview

Phase: Phase 1
Intervention: Venetoclax
Conditions: Relapsed Non Hodgkin Lymphoma
Sponsor: Nordic Lymphoma Group
Enrollment: 59
Locations: 17
Primary Endpoint: Overall response rate
Last Updated: 4 years ago

Overview Investigators Eligibility Criteria Arms & Interventions Outcomes Sites Similar Trials

Overview

Brief Summary

Phase I/II trial, with the aim of evaluating the efficacy of venetoclax to the backbone of rituximab-lenalidomide in patients with relapsed/refractory MCL.

Registry

clinicaltrials.gov

Start Date

July 1, 2018

End Date

December 1, 2022

Last Updated

4 years ago

Study Type

Interventional

Study Design

Single Group

Sex

All

Investigators

Sponsor

Nordic Lymphoma Group

Responsible Party

Sponsor

Eligibility Criteria

Inclusion Criteria

Not provided

Exclusion Criteria

Not provided

Arms & Interventions

Treatment

Venetoclax+lenalidomide+rituximab

Intervention: Venetoclax

Outcomes

Primary Outcomes

Overall response rate

Time Frame: 6 months

The primary objective is to assess the overall response rate (ORR) at 6 months with lenalidomide-venetoclax and rituximab, in patients with relapsed or refractory mantle cell lymphoma, by use of an MRD driven strategy. ORR includes complete (CR) and partial remissions (PR).